ReviewInternational journal of molecular sciences2020
The Role of the Gut Microbiome in Liver Cirrhosis Treatment.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- [Efficacy of different doses of magnesium isoglycyrrhizinate in the treatment of chronic liver disease with elevated ALT: a meta-analysis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Pooled it
- Voluntary wheel running modulates murine gut microbiome during hyperammonemic stress.Microbiology spectrum · 2026Article
- Gut Microbiota Dysbiosis and LPS/NLRP3/GSDMD Pyroptosis Drive Hepatic Fibrosis: Therapeutic Potential of a Synbiotic Intervention.Probiotics and antimicrobial proteins · 2026Article
- Article
- Pathogen distribution, antimicrobial resistance, and gut microbiota dysbiosis in patients with cirrhosis complicated by infection in northwestern China.Frontiers in microbiology · 2026Article
- Predictive Value of Procalcitonin and C-reactive Protein for Mortality in Live Donor Liver Transplant Recipients.Cureus · 2025Article
- Microbial Metabolites and Cardiovascular Dysfunction: A New Era of Diagnostics and Therapy.Cells · 2025Review
- Review
- Trends and hotspots in autoimmune hepatitis research: based on bibliometric analysis.Hereditas · 2025Review
- Gut Microbiota and the Gut-Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies.Microorganisms · 2025Review
- Quantification ofWorld journal of hepatology · 2025Article
- Multi-omics analysis of host-microbiome interactions in a mouse model of congenital hepatic fibrosis.BMC microbiology · 2025Article
- Comprehensive toolkit integrating lifestyle and clinical questionnaires with gut microbiota profiling via rectal swabs: application in intensive care cirrhotic patients.Journal of medical microbiology · 2025Article
- Gut‑liver axis in liver disease: From basic science to clinical treatment (Review).Molecular medicine reports · 2025Review
- Stem cell therapy for chronic diffuse liver lesions: main symptoms and causes.Przeglad gastroenterologiczny · 2025Article
- Research progress on nutritional support for patients with liver cirrhosis complicated by upper gastrointestinal bleeding.Frontiers in nutrition · 2025Review
- Modular mastery of inflammation: umbilical cord mesenchymal stem cells as a therapeutic frontier.Frontiers in immunology · 2025Review
- Gut microbiota dysbiosis in infantile cholestatic hepatopathy.Frontiers in pediatrics · 2025Article
- Correlation between differences in the intestinal flora structure and Chinese medicine evidence in patients with Wilson disease-related liver fibrosis analyzed via high-throughput sequencing technology.Bioscience of microbiota, food and health · 2025Article
- Microbiota composition and intestinal barrier function modulated by tamsulosin andFrontiers in cellular and infection microbiology · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Liver cirrhosis is one of the most prevalent chronic liver diseases worldwide. In addition to viral hepatitis, diseases such as steatohepatitis, autoimmune hepatitis, sclerosing cholangitis and Wilson's disease can also lead to cirrhosis. Moreover, alcohol can cause cirrhosis on its own and exacerbate chronic liver disease of other causes. The treatment of cirrhosis can be divided into addressing the cause of cirrhosis and reversing liver fibrosis. To this date, there is still no clear consensus on the treatment of cirrhosis. Recently, there has been a lot of interest in potential treatments that modulate the gut microbiota and gut-liver axis for the treatment of cirrhosis. According to recent studies, modulation of the gut microbiome by probiotics ameliorates the progression of liver disease. The precise mechanism for relieving cirrhosis via gut microbial modulation has not been identified. This paper summarizes the role and effects of the gut microbiome in cirrhosis based on experimental and clinical studies on absorbable antibiotics, probiotics, prebiotics, and synbiotics. Moreover, it provides evidence of a relationship between the gut microbiome and liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.